

CLAIMS

1) Use of a monovalent antibody fragment directed against the EC2 domain of the Fc α RI receptor, as anti-inflammatory active principle for the preparation of
5 a medicament for treating an inflammatory disease.

2) Use according to claim 1, wherein said inflammatory disease is selected among lupus, rheumatoid arthritis, diabetes, nephritis interstitial renal fibrosis, obstructive nephropathy, and gut inflammatory
10 disorders.

3) Use according to claim 1, wherein said disease is an allergic disease.

4) Use according to claim 3, wherein said allergic disease is asthma.